Eyeing the Future: Stem Cell Therapy Landscape in Ophthalmology

Abstract

The eye's immune-privileged status and unique anatomical accessibility make it an ideal target for regenerative medicine. Over the past two decades, stem cell-based therapies have emerged as transformative approaches for blinding ocular disorders that currently lack curative treatments. Advances in cell biology, bioengineering, and high-resolution ocular imaging have accelerated the translation of stem cell technologies from bench to bedside, particularly for posterior segment diseases such as Age-Related Macular Degeneration (AMD), Inherited Retinal Dystrophies (IRDs), and glaucoma. Retinal pigment epithelial cell transplantation and gene-corrected Induced Pluripotent Stem Cells (iPSCs) have demonstrated encouraging safety and preliminary efficacy in early-phase trials for IRDs. Parallel strategies targeting Retinal Ganglion Cell (RGC) loss in glaucoma—currently managed solely by intraocular pressure reduction—include stem cell-derived RGC replacement and neuroprotective paracrine signaling by Mesenchymal Stem Cells (MSCs). Similarly, Limbal Stem Cell Deficiency (LSCD) and corneal scarring, major causes of blindness in low-resource settings, are increasingly addressed through ex vivo expansion and transplantation of autologous or allogeneic limbal stem cells. Pluripotent and adult stem cell sources, including embryonic stem cells, iPSCs, and MSCs, have been differentiated into Retinal Pigment Epithelium (RPE), photoreceptors, and corneal epithelial cells with increasing fidelity. MSC-derived extracellular vesicles (EVs) represent a particularly promising cell-free therapeutic strategy, delivering neurotrophic and immunomodulatory factors that preserve retinal structure and function in degenerative models. Recent trials confirm favorable safety profiles and early signals of efficacy in conditions such as retinitis pigmentosa and glaucoma. Concurrently, innovations in cell delivery systems, scaffold engineering, and immune modulation continue to refine engraftment outcomes and reduce off-target effects. This review synthesizes current clinical and preclinical evidence across major ocular conditions, highlights emerging bioengineering and regulatory considerations, and delineates future directions for stem cell-based interventions aimed at restoring vision and preventing irreversible blindness.